Cited 1630 times in
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권혁문 | - |
dc.contributor.author | 정남식 | - |
dc.date.accessioned | 2020-02-11T02:22:53Z | - |
dc.date.available | 2020-02-11T02:22:53Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/174490 | - |
dc.description.abstract | BACKGROUND: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control. METHODS: This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo. Randomisation was done by a computer-generated random code with stratification by site. All investigators and participants were masked to treatment assignment. Participants were followed up at least every 6 months for incident cardiovascular and other serious clinical outcomes. The primary outcome was the first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes), which was assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01394952. FINDINGS: Between Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66·2 years [SD 6·5], median HbA1c 7·2% [IQR 6·6-8·1], 4589 [46·3%] women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). During a median follow-up of 5·4 years (IQR 5·1-5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79-0·99; p=0·026). All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80-1·01; p=0·067). 2347 (47·4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1687 (34·1%) participants assigned to placebo (p<0·0001). INTERPRETATION: Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors. FUNDING: Eli Lilly and Company. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | LANCET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cardiovascular Diseases/mortality | - |
dc.subject.MESH | Cardiovascular Diseases/prevention & control* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/complications | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glucagon-Like Peptides/analogs & derivatives* | - |
dc.subject.MESH | Glucagon-Like Peptides/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/therapeutic use* | - |
dc.subject.MESH | Immunoglobulin Fc Fragments/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/prevention & control | - |
dc.subject.MESH | Recombinant Fusion Proteins/therapeutic use* | - |
dc.subject.MESH | Stroke/prevention & control | - |
dc.title | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hertzel C Gerstein | - |
dc.contributor.googleauthor | Helen M Colhoun | - |
dc.contributor.googleauthor | Gilles R Dagenais | - |
dc.contributor.googleauthor | Rafael Diaz | - |
dc.contributor.googleauthor | Mark Lakshmanan | - |
dc.contributor.googleauthor | Prem Pais | - |
dc.contributor.googleauthor | Jeffrey Probstfield | - |
dc.contributor.googleauthor | Jeffrey S Riesmeyer | - |
dc.contributor.googleauthor | Matthew C Riddle | - |
dc.contributor.googleauthor | Lars Rydén | - |
dc.contributor.googleauthor | Denis Xavier | - |
dc.contributor.googleauthor | Charles Messan Atisso | - |
dc.contributor.googleauthor | Leanne Dyal | - |
dc.contributor.googleauthor | tephanie Hall | - |
dc.contributor.googleauthor | Purnima Rao-Melacini | - |
dc.contributor.googleauthor | Gloria Wong | - |
dc.contributor.googleauthor | Alvaro Avezum | - |
dc.contributor.googleauthor | Jan Basile | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.contributor.googleauthor | Ignacio Conget | - |
dc.contributor.googleauthor | William C Cushman | - |
dc.contributor.googleauthor | Edward Franek | - |
dc.contributor.googleauthor | Nicolae Hancu | - |
dc.contributor.googleauthor | Markolf Hanefeld | - |
dc.contributor.googleauthor | Shaun Holt | - |
dc.contributor.googleauthor | Petr Jansky | - |
dc.contributor.googleauthor | Matyas Keltai | - |
dc.contributor.googleauthor | Fernando Lanas | - |
dc.contributor.googleauthor | Lawrence A Leiter | - |
dc.contributor.googleauthor | Patricio Lopez-Jaramillo | - |
dc.contributor.googleauthor | Ernesto German Cardona Munoz | - |
dc.contributor.googleauthor | Valdis Pirags | - |
dc.contributor.googleauthor | Nana Pogosova | - |
dc.contributor.googleauthor | Peter J Raubenheimer | - |
dc.contributor.googleauthor | Jonathan E Shaw | - |
dc.contributor.googleauthor | Wayne H-H Sheu | - |
dc.contributor.googleauthor | Theodora Temelkova-Kurktschiev | - |
dc.contributor.googleauthor | for the REWIND Investigators | - |
dc.identifier.doi | 10.1016/S0140-6736(19)31149-3 | - |
dc.contributor.localId | A00260 | - |
dc.relation.journalcode | J02152 | - |
dc.identifier.eissn | 1474-547X | - |
dc.identifier.pmid | 31189511 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0140673619311493 | - |
dc.contributor.alternativeName | Kwon, Hyuck Moon | - |
dc.contributor.affiliatedAuthor | 권혁문 | - |
dc.citation.volume | 394 | - |
dc.citation.number | 10193 | - |
dc.citation.startPage | 121 | - |
dc.citation.endPage | 130 | - |
dc.identifier.bibliographicCitation | LANCET, Vol.394(10193) : 121-130, 2019 | - |
dc.identifier.rimsid | 64394 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.